잠시만 기다려 주세요. 로딩중입니다.

Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure

대한간암학회지 2020년 20권 1호 p.72 ~ 77
김재웅, 장진원, 박준영,
소속 상세정보
김재웅 ( Kim Jae-Woong ) - Yonsei University College of Medicine Department of Internal Medicine
장진원 ( Chang Jin-Won ) - Yonsei University College of Medicine Department of Internal Medicine
박준영 ( Park Jun-Young ) - Yonsei University College of Medicine Department of Internal Medicine

Abstract


Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line therapy that has been globally approved after progression under sorafenib treatment. Recently, immunotherapeutic agents have emerged as promising treatment options in many different malignancies, including advanced HCC. Nivolumab is the first immunotherapy approved by the Food and Drug Administration for use in HCC patients with advanced-stage second-line after sorafenib failure. In this report, a case of advanced HCC with multiple lung metastases in which a complete response and maintained progression-free status was achieved with nivolumab, following the failure of transarterial chemoembolization and sorafenib is presented. We hope this report may help expand the clinical application of second-line treatment.

키워드

Hepatocellular carcinoma; Lung metastasis; Sorafenib failure; Immunotherapy; Nivolumab

원문 및 링크아웃 정보

 

등재저널 정보